Ken Griffin Beam Therapeutics Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$22.57 - $33.14 $616,161 - $904,722	-27,300 Reduced 31.6%	59,100 $1.45 Million
Q2 2024 Aug 14, 2024	SELL	$21.22 - $32.66 $454,108 - $698,923	-21,400 Reduced 19.85%	86,400 $2.02 Million
Q1 2024 May 15, 2024	BUY	$23.46 - $45.07 $1.39 Million - $2.67 Million	59,300 Added 122.27%	107,800 $3.56 Million
Q4 2023 Feb 14, 2024	SELL	$17.69 - $30.76 $905,728 - $1.57 Million	-51,200 Reduced 51.35%	48,500 $1.32 Million
Q3 2023 Nov 14, 2023	BUY	$23.01 - $32.46 $925,002 - $1.3 Million	40,200 Added 67.56%	99,700 $2.4 Million
Q2 2023 Aug 14, 2023	SELL	$29.32 - $35.99 $2.28 Million - $2.8 Million	-77,800 Reduced 56.66%	59,500 $1.9 Million
Q1 2023 May 15, 2023	SELL	$30.15 - $48.79 $1.18 Million - $1.91 Million	-39,200 Reduced 22.21%	137,300 $4.2 Million
Q4 2022 Feb 14, 2023	BUY	$36.73 - $51.6 $2.57 Million - $3.61 Million	69,900 Added 65.57%	176,500 $6.9 Million
Q3 2022 Nov 14, 2022	BUY	$39.79 - $70.31 $374,026 - $660,914	9,400 Added 9.67%	106,600 $5.08 Million

236

75.2M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.72B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.